Source library / Last editorial review August 2026
Each source below has a specific job. Regulatory documents establish approved labeling. Registries describe study plans. Research summaries explain scientific context. None replaces individualized care.
Drug information
MedlinePlus / U.S. National Library of Medicine
Useful for: Patient-facing summary of approved uses, precautions, interactions, and serious risks.
Does not establish: General information cannot assess an individual patient.
Prescribing information
U.S. Food and Drug Administration
Useful for: Regulatory source for indications, warnings, contraindications, and prescribing details.
Does not establish: The linked label is a public FDA document; readers and clinicians should verify the latest approved labeling.
Research context
National Institute on Aging
Useful for: Explains geroscience interest in compounds including rapamycin and distinguishes animal findings from human questions.
Does not establish: Research context is not a treatment recommendation.
Registered study
ClinicalTrials.gov / U.S. National Library of Medicine
Useful for: Registry record for a human study of rapamycin and everolimus in older adults.
Does not establish: Registration describes a study plan. It is not a favorable result or proof of benefit.
Consumer protection
U.S. Food and Drug Administration
Useful for: FDA guidance about unsupported disease and anti-aging medication claims.
Does not establish: It does not evaluate every individual product, clinic, or practitioner.
Editorial method
1. Label the evidence. Approved use, human outcome, animal finding, mechanism, and expert opinion are not interchangeable.
2. Preserve the boundary. We state what a source supports and what it does not.
3. Date the review. Medical evidence and regulatory information change. Readers should verify current sources.